Welcome to our dedicated page for Protalix Biother SEC filings (Ticker: PLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding Protalix BioTherapeutics’ SEC disclosures can feel like reading a graduate-level biology text. Clinical trial data, royalty structures with Pfizer and Chiesi, and the cash runway behind the ProCellEx plant-based platform are scattered across hundreds of pages. Missing a single FDA update buried in an 8-K or the timing of a milestone payment in a 10-Q could change your valuation model. Stock Titan’s AI turns those complexities into clear narratives within minutes. For SEC newcomers, Protalix BioTherapeutics SEC filings explained simply is not a slogan—it’s our deliverable.
Whether you need the full Protalix BioTherapeutics annual report 10-K simplified or real-time alerts on Protalix BioTherapeutics insider trading Form 4 transactions, our platform has you covered. Every filing flows from EDGAR to our dashboard instantly; AI highlights pipeline progress, R&D spend, and liquidity trends, then links you straight to the source page. Typical queries investors ask are surfaced below so you can jump right in:
- Protalix BioTherapeutics quarterly earnings report 10-Q filing
- Protalix BioTherapeutics Form 4 insider transactions real-time
- Protalix BioTherapeutics proxy statement executive compensation
- Protalix BioTherapeutics 8-K material events explained
- understanding Protalix BioTherapeutics SEC documents with AI
- Protalix BioTherapeutics earnings report filing analysis
- Protalix BioTherapeutics executive stock transactions Form 4
From gauging how many quarters of cash the company holds to tracking Fabry-trial milestones, you’ll see the data in context. Our expert commentary pairs AI summaries with plain-English explanations of each risk factor, so you can compare quarter-over-quarter R&D expenses or monitor Form 4 buying ahead of FDA decisions without wading through footnotes. Take the guesswork out of Protalix BioTherapeutics SEC filings—start reading only what matters.
Protalix BioTherapeutics filed a pre-effective amendment to its Form S-3 as an exhibits-only filing to include an updated auditor consent from Kesselman & Kesselman (a PwC Israel member firm). The amendment consists solely of the facing page, an explanatory note, Item 16 with the exhibit index, the signature page and the filed exhibits; the prospectus is unchanged and has been omitted. The filing includes signatures by Dror Bashan and other officers and directors.
Protalix BioTherapeutics (PLX) reported consolidated revenue of $25.8 million for the six months ended June 30, 2025, up from $17.2 million a year earlier, driven by product sales to Pfizer, Fiocruz and Chiesi. The company narrowed its six-month net loss to $3.5 million from $6.8 million a year ago and recorded a $0.16 million net income in the three months ended June 30, 2025. Cash and cash equivalents were $17.9 million with short-term bank deposits of $15.5 million, total assets of $78.5 million and stockholders' equity of $49.9 million.
The company generated $6.8 million net proceeds from at-the-market sales under the Sales Agreement during the six-month period and stated that cash and short-term deposits are sufficient to satisfy capital needs for at least 12 months. Commercial activities include marketed products Elfabrio and Elelyso with commercialization partners Chiesi and Pfizer, ongoing clinical programs (PRX-115, PRX-119) and manufacturing responsibilities for approved products. The filing also discloses potential operational exposure to the Israel conflict and steps taken to mitigate supply risk.
Protalix BioTherapeutics, Inc. disclosed that it furnished a press release announcing its financial results for the fiscal quarter ended June 30, 2025 and provided a business and clinical update. The press release is furnished as Exhibit 99.1 to the Current Report on Form 8-K. The filing notes that the furnished information is not deemed "filed" under Section 18 of the Exchange Act and, therefore, is not incorporated by reference into registration statements or other filings unless specifically stated.
Protalix BioTherapeutics director Aharon Schwartz purchased 129,000 shares of Protalix (PLX) common stock on 06/10/2025 at a weighted average price of $1.596 per share, with execution prices ranging from $1.575 to $1.60 across multiple trades. Following the reported purchase, the reporting person beneficially owned 303,000 shares.
The filing identifies Mr. Schwartz as a director and shows the transaction coded as a purchase. The report notes the transaction was executed in multiple trades and that the reporting person will provide full trade-by-trade details upon request to the SEC staff, the issuer, or a security holder.
Protalix BioTherapeutics (NYSE:PLX) filed an 8-K disclosing the results of its 2025 Annual Meeting held on June 26, 2025.
- Eight directors elected: top nominee received 22.4 M votes for versus 1.9 M withheld; 12.7 M broker non-votes across the slate.
- Say-on-pay approved: 16.4 M for, 7.5 M against, 0.38 M abstentions, 12.7 M broker non-votes.
- PwC Israel ratified as auditor for FY 2025: 34.9 M for, 1.6 M against, 0.46 M abstentions.
No additional material actions or strategic updates were reported.
FAQ
What is the current stock price of Protalix Biother (PLX)?
What is the market cap of Protalix Biother (PLX)?
